Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | MMP1 | P03956 | 3/20 | 0.71 |
| ▸ | MMP2 | P08253 | 3/20 | 0.71 |
| ▸ | MMP9 | P14780 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idrocilamide SCHEMBL1171234 | 1.00 | KMT2A (0.77) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL11590847 | 0.91 | KMT2A (0.86) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL27093064 | 0.90 | KMT2A (0.84) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL27093051 | 0.90 | KMT2A (0.84) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL1193088 | 0.88 | KMT2A (0.81) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL27093061 | 0.88 | KMT2A (0.81) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL25193280 | 0.87 | KMT2A (1.00) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL3208177 | 0.87 | KMT2A (0.93) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL27093047 | 0.87 | KMT2A (0.79) | KMT2AMMP1MMP2MMP9POLB | |
| SCHEMBL27093034 | 0.87 | KMT2A (0.79) | KMT2AMMP1MMP2MMP9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068949-A1 | EMRUSOLMIN FOR USE IN TREATING MULTIPLE SYSTEM ATROPHY | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2025-04-03 | — | — | WO | claimed |
| WO-2025062440-A1 | TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF | PULSE PHARMACEUTICALS PVT. LTD (IN) | 2025-03-27 | — | — | WO | claimed |
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION | 2022-05-19 | — | — | US | claimed |
| EP-3923920-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | The Ketamine Research Foundation (US) | 2021-12-22 | — | — | EP | claimed |
| CN-112898816-B | Photosensitive leveling wetting dispersant for optical fiber coloring ink and preparation method and application thereof | 武汉长盈鑫科技有限公司 | 2021-11-16 | — | — | CN | claimed |
| CN-112898816-A | Photosensitive leveling wetting dispersant for optical fiber coloring ink and preparation method and application thereof | 武汉长盈鑫科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2021-04-22 | — | — | US | claimed |
| WO-2021026232-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | THE KETAMINE RESEARCH FOUNDATION (US) | 2021-02-11 | — | — | WO | claimed |
| EP-3548014-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | Wolfson, Philip, E. (US) | 2019-10-09 | — | — | EP | claimed |
| WO-2018102488-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | WOLFSON PHILIP E (US) | 2018-06-07 | — | — | WO | claimed |
| US-20050008702-A1 | Rupturing controlled release device having a preformed passageway | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2005-01-13 | — | — | US | claimed |
| WO-2004112723-A2 | TROPICAL THERAPY FOR THE TREATMENT OF MIGRAINES, MUSCLE SPRAINS, MUSCLE SPASM, SPASTICITY AND RELATED CONDITIONS | AUNG-DIN RONALD (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040204413-A1 | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant | OSMOTICA CORP. (VG) | 2004-10-14 | — | — | US | claimed |
| EP-1362585-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING A COX-II INHIBITOR AND A MUSCLE RELAXANT | Osmotica Corp. (VG) | 2003-11-19 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0341745-B1 | Crosslinked carboxy polysaccharides | FIDIA SPA (IT) | 1994-12-14 | — | — | EP | claimed |
| EP-0094283-B1 | SUSTAINED-RELEASE THEOPHYLLIN DRUG FORMULATION | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1985-11-21 | — | — | EP | claimed |
| US-4512994-A | ANTIASTHMATIC AGENTS;BRONCHO DILATORS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1985-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151955-A1 | KETAMINE FOR THE TREATMENT OF POSTPARTUM SYMPTOMS AND DISORDERS | OXTR, PNISR, KCNQ5 | KMT2A 228/4885MMP1 4066/4885MMP2 3594/4885 |
| US-20210113493-A1 | KETAMINE FOR THE TREATMENT OF MENSTRUALLY RELATED SYMPTOMS | KCNK5, KCNQ5, KCND2 | KMT2A 143/4885MMP1 4382/4885MMP2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.